In:
Diabetes & Metabolism Journal, Korean Diabetes Association, Vol. 46, No. 5 ( 2022-09-30), p. 701-712
Abstract:
Background: To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in Korean patients with type 2 diabetes mellitus (T2DM).Methods: Prescription patterns of SGLT2i use between 2015 and 2019 were determined using the Korean National Health Insurance Service database of claims.Results: Of all patients with T2DM ( 〈 i 〉 n 〈 /i 〉 =4,736,493), the annual prescription rate of SGLT2i increased every year in patients with ASCVD (from 2.2% to 10.7%) or HF (from 2.0% to 11.1%). After the first hospitalization for ASCVD ( 〈 i 〉 n 〈 /i 〉 =518,572), 13.7% ( 〈 i 〉 n 〈 /i 〉 =71,259) of patients initiated SGLT2i with a median of 10.6 months. After hospitalization for HF ( 〈 i 〉 n 〈 /i 〉 =372,853), 11.2% ( 〈 i 〉 n 〈 /i 〉 =41,717) of patients initiated SGLT2i after a median of 8.8 months. In multivariate regression for hospitalization, older age (per 10 years, odds ratio [OR], 0.57; 95% confidence interval [CI] , 0.56 to 0.57), lower household income (OR, 0.93; 95% CI, 0.92 to 0.95), rural residents (OR, 0.95; 95% CI, 0.93 to 0.97), and dipeptidyl peptidase-4 inhibitor (DPP-4i) users (OR, 0.82; 95% CI, 0.81 to 0.84) were associated with lesser initiation of SGLT2i in ASCVD. Additionally, female gender (OR, 0.97; 95% CI, 0.95 to 0.99) was associated with lesser initiation of SGLT2i in HF.Conclusion: The prescription rate of SGLT2i increased gradually up to 2019 but was suboptimal in patients with ASCVD or HF. After the first hospitalization for ASCVD or HF, older age, female gender, low household income, rural residents, and DPP-4i users were less likely to initiate SGLT2i.
Type of Medium:
Online Resource
ISSN:
2233-6079
,
2233-6087
DOI:
10.4093/dmj.2022.0002
Language:
English
Publisher:
Korean Diabetes Association
Publication Date:
2022
detail.hit.zdb_id:
2602402-0
Bookmarklink
